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Accepted 26 October 2015; Published online 5 November 2015AbstractObjectives: Patient care decisions demand high-quality research. To assist those decisions, numerous observational studies are
being performed. Are the standards and guidelines to assess observational studies consistent and actionable? What policy considerations
should be considered to ensure decision makers can determine if an observational study is of high-quality and valid to inform treatment
decisions?
Study Design and Setting: Based on a literature review and input from six experts, we compared and contrasted nine standards/
guidelines using 23 methodological elements involved in observational studies (e.g., study protocol, data analysis, and so forth).
Results: Fourteen elements (61%) were addressed by at least seven standards/guidelines; 12 of these elements disagreed in the
approach. Nine elements (39%) were addressed by six or fewer standards/guidelines. Ten elements (43%) were not actionable in at least
one standard/guideline that addressed the element.
Conclusion: The lack of observational study standard/guideline agreement may contribute to variation in study conduct; disparities in
what is considered credible research; and ultimately, what evidence is adopted. A common set of agreed on standards/guidelines for con-
ducting observational studies will benefit funders, researchers, journal editors, and decision makers.  2016 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Patient care and policy decisions demand high-quality
evidence. Some have hypothesized that the volume, veloc-
ity, and veracity of observational data from electronic
health records, administrative claims, and investment in
data networks can be positioned to meet this demand.
Despite the increased availability of data, lack of accep-
tance of observational studies by clinical and nonclinical
decision makers may be due to unfamiliarity with the
methods used or variability in study quality [1e4]. Defi-
cient studies may lead to misuse of resources and result
in poor health care outcomes for patients.
To improve the quality of observational studies conduct-
ed and reported, standards and guidelines by scientific,
regulatory, and government organizations have proliferatedFunding: This research was funded by the National Pharmaceutical
Council and the University of Pittsburgh (grant number: 709233).
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licenses/by-nc-nd/4.0/).over the past 5 to 10 years. Some documents serve as pre-
requisites for accessing specific data sets or obtaining fund-
ing [5]. A recent international initiative, STRengthening
Analytical Thinking for Observational Studies, has been
launched to provide guidance in the design and analysis
of observational studies [4]. Among the various standards/
guidelines, differences may exist based on purpose (e.g.,
conducting vs. reporting vs. evaluating research),
philosophy (e.g., best practices vs. minimum standards),
or format (checklist vs. explanatory primer).
The use of real-world evidence is critical to transforming
health care, and policies need to address this issue.
Although the availability of multiple standards/guidelines
has the potential to improve the quality and credibility of
observational studies, there may be unintended conse-
quences. If those guidelines differ from one another, deci-
sions based on one guideline may subsequently be found
deficient if measured against a different one. Not having
a ‘‘gold standard’’ becomes problematic for: (1) funders
evaluating the merits of proposed research, (2) researchers
seeking to use the most appropriate methods, (3) journal
editors and reviewers assessing the quality of researchess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 Nine major standards/guidelines for observational
studies have areas of disagreement based on a
comparison of 23 common elements.
What this adds to what was known?
 Comparison of the standards/guidelines is pre-
sented, along with an assessment of how actionable
each is, and a policy discussion of next steps is
provided.
What is the implication and what should change
now?
 Lack of standard/guideline agreement may
contribute to variation in study conduct.
 Common standards/guidelines for conducting
observational studies will benefit funders, re-
searchers, journal editors, and decision makers.
 A consensus process to determine a common set of
standards/guidelines needs to be established.
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We sought to understand the commonalities and differ-
ences among standards/guidelines for observational studies
and to determine how great a challenge exists. Based on this
review, we outline the policy implication of standards/
guidelines that are not uniform and focus on areas for future
methods development and consensus and describe the
benefits and potential harms associated with a common or
harmonized set of standards/guidelines and optimal
approach. To accomplish these objectives, we first conducted
a detailed literature search to identify standards and guide-
lines. We then compared and contrasted the existence or lack
thereof of specific methodological elements (and the
actionability of those elements) associated with the research
plan development, data collection and study implementation,
analysis, discussion, and conclusions. Finally, we examine
whether there are benefits and harms associated with a
common or harmonized set of standards/guidelines and the
optimal approach for harmonization.ArƟcles included in 
qualitaƟve synthesis
(n = 11)
Corresponds to 9 
standards/guidelines
Focused on a specific condiƟon, 
reporƟng for a specific journal or did not 
directly address observaƟonal study 
research (n = 42)
Data-related (n = 7)
Case control studies only (n = 1)
Review of quality assessment tool (n = 1)
Fig. 1. PRISMA flow diagram.2. Methods
We conducted a detailed literature search, identified
salient standards/guidelines for observational studies, and
compared and contrasted the standards/guidelines. We
engaged a team of six international methodology expertsfrom academia, government, and industry to provide insight
and advice throughout each stage of the project.
First, we conducted a detailed literature search to iden-
tify applicable standards/guidelines for observational
studies from regulatory bodies, government agencies, pro-
fessional organizations, initiatives, or collaborations. With
the assistance of a medical librarian, we searched PubMed
from January 1, 1947, to August 6, 2015, and also received
gray literature citations from our experts, retrieving 3,812
citations (see Preferred Reporting Items for Systematic
Reviews and Meta-Analyses [PRISMA] diagram [6],
Fig. 1). A single reviewer examined titles and abstracts to
identify articles that referred to standards, guidelines,
consensus development conferences, or outstanding issues
in the design, conduct, or reporting of observational studies.
Dual data abstraction was conducted on the resulting 211
articles. One hundred forty-nine articles were excluded
because they were either duplicative or did not address
observational study research.
Next, based on input from our experts, we developed a set
of inclusion criteria to focus on standards/guidelines for
doing observational research. We thus excluded articles that
were focused on methods for evaluating a specific condition
(e.g., rheumatology), did not directly address observational
study designs (e.g., were related to standards for systematic
reviews or meta-analyses), or were standards/guidelines for
reporting studies in journals (Fig. 1). After applying these
criteria, 11 articles remained. These articles corresponded
to nine standards/guidelines because three articles are
content related and created by the same organization
[79]. The nine standards/guidelines are as follows: Agency
for Healthcare Research Quality (AHRQ): Developing a
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Research [10]; Comparative Effectiveness Research Collab-
orative: Observational Study Assessment Questionnaire
[11]; European Network of Centres for Pharmacoepidemiol-
ogy and Pharmacovigilance (ENCePP) Checklist for Study
Protocols [12]; ENCePPGuide onMethodological Standards
in Pharmacoepidemiology [13]; The United States Food and
Drug Administration (FDA): Guidance for Industry Good
Pharmacovigilance Practices and Pharmacoepidemiologic
Assessment [14]; Good ReseArch for Comparative Effec-
tiveness (GRACE) Checklist [15]; GRACE Principles [16];
ISPOR Good Research Practices for Retrospective Database
Analysis Task Force Report (Parts I, II, and III combined)
[79]; and Patient-Centered Outcomes Research Institute
(PCORI) Methodology Standards [17].2.1. Data collection in a primary content table
Two team members independently reviewed all nine
standards/guidelines. We then created a framework to
compare them (Supplemental Material/Appendix at www.
jclinepi.com). The framework was modeled after the
comprehensive GRACE framework which outlines various
steps associated with conducting a study and are typically
found in a study publication (e.g., research plan, study
methods, data analysis, discussion, interpretation, and
conclusion). After testing this approach with our experts,
we added unique elements from the other selected
standards/guidelines. In this framework, each standard/
guideline represented a column and each row corresponded
to 23 observational study elements. The table cells contain
the related standard/guideline content. We duplicated a
standard/guideline’s content across elements, if appro-
priate, because we wanted to understand if specific stan-
dards/guidelines addressed a topic and if there was
variation in the elements addressed. For example, potential
bias was addressed by some standards/guidelines
throughout the standard/guideline (e.g., when selecting
the treatment comparators, in the study protocol of the
research plan, in the analysis phase via conducting sensi-
tivity analysis, and in the interpretation and bias section
of discussion and conclusion), whereas others addressed
bias in only a single element.
Some standards/guidelines did not offer a single recom-
mendation for an element, but instead offered a choice in
recommended actions. For example, GRACE 2.0 notes that
‘‘if one or more comparison groups were used, were they
concurrent comparators? If not, did the authors justify the
use of historical comparison group(s)?’’ allowing for
choice. We recorded such choices in content within table
cells.2.2. Element summarization
We summarized each element (row) by taking
into consideration the number of standards/guidelines(columns) addressing the issue, as well as similarities,
differences, and choices. We categorized each element
based on the number of standards/guidelines that addressed
the element:
 7e9 standards/guidelines addressed the element and
content agreed across the standards/guidelines
(green);
 7e9 standards/guidelines addressed the element, but
content did not agree across the standards/guidelines
(blue);
 4e6 standards/guidelines addressed the element
(yellow);
 1e3 standards/guidelines addressed the element
(red).
Table 1 lists the results of this element summarization.
The colors in Table 1 correspond to the four categories
shown previously.2.3. Actionability assessment
For each standard/guideline, we analyzed each element to
determine if the standard/guideline advice (cell) was action-
able. We defined actionable as, ‘‘A researcher has a two-part
evaluation process for each component outlined in the nine
standards/guidelines when doing an observational study.
First, the researcher should clearly know that an element
should be addressed. Second, if the element is included, then
the researcher should understand the steps of that element
and the level of detail required for fulfillment. If both these
criteria aremet, then the element is actionable.’’ For example,
the FDA Guidance for Industry Good Pharmacovigilance
Practices and PharmacoepidemiologicAssessment notes that
a hypothesis should be prespecified, but the guidance does
not meet the second requirement describing how this should
be done. However, for a separate element, the elements
recommended by the FDA Guidance for industry are laid
out clearly. If the element itself is notmentioned, we note that
it is not addressed. For those standards/guidelines that
addressed each element, we calculated the percent which
provided actionable information. Table 2 lists the results of
this actionability assessment.3. Results
Each of the nine standards/guidelines had an intended,
self-identified audience: five targeted researchers, three
decision makers, one stakeholders, and one industry. The
focus of the standards/guidelines varied with five focused
on comparative effectiveness research (CER), three on
pharmacoepidemiological or pharmacovigilance studies,
and one on patient-centered outcomes research (PCOR),
or arguably PCOR-CER. The format of the guidelines/
standards also varied from journal articles, documents
with web resources, a multiple-chapter document,
Table 1. Summary
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questionnaire.3.1. Comparison of standards/guidelines
Of 23 methodological elements, 14 (61%) were
addressed by seven or more standards/guidelines (green
or blue in Table 1). For two of the elements (9%), content
agreed among at least seven standards/guidelines (green in
Table 1). An example of agreement is the ‘‘study objectives
and research questions’’ element. Eight standards/
guidelines include reference to research questions and/or
objectives of the study being defined before the study being
conducted. Two standards/guidelines specifically outline
the study objective to be based on the PICOTS/PICO
[e.g., Population (P), Intervention (I), Comparator (C),
Outcomes (O), Timing (T) and Setting (S)]. For 12 of
the elements (52%), the content was addressed by seven
to nine standards/guidelines, but those standards/guidelines
disagreed on the approach or recommended actions (blue inTable 1). The standards/guidelines that addressed the
element thus considered it important but did not agree on
how to best address the element. An example is the missing
data element. Although seven standards/guidelines mention
missing data and six want information on the management
of missing data, they differed in how missing data should
be handled. For example, one standard/guideline suggested
using mean value imputation, whereas others suggest other
imputation methods, such as substitution of a predicted
value from a regression model, hotdeck imputation,
imputation based on a Bayesian approach, or multiple
imputation.
Five elements (22%) were addressed by between four to
six standards/guidelines (yellow in Table 1). An example is
data linkage with five standards/guidelines addressing this
element. Data linkage encompasses the study’s plan on
how to link data from two or more sources, such as regis-
tries and data networks, while taking into consideration
quality and accuracy. Across the standards/guidelines,
groups noted the challenges associated with merging
Table 2. Actionability assessment
Aspect of observational study Actionable
Not
actionable
Not
addressed
Content actionable
(%)
Research plan
Review of prior research 6 0 3 6 of 6 (100)
Study objectives and research questions 8 0 1 8 of 8 (100)
Hypotheses 5 1 3 5 of 6 (83)
Communication with stakeholders 2 0 7 2 of 2 (100)
Study protocol 7 1 1 7 of 8 (87)
Study design 5 1 3 5 of 6 (83)
Study limitations and potential confounders 7 1 1 7 of 8 (87)
Population including inclusion/exclusion criteria 8 1 0 8 of 9 (88)
Comparators, comparison groups, and exposure 9 0 0 9 of 9 (100)
Sample size and statistical power 8 0 1 8 of 8 (100)
Measures, end points, and outcomes 8 0 1 8 of 8 (100)
Methods
Data sources, including collection, coding, capture, and storage 8 1 0 8 of 9 (88)
Data linkage 4 1 4 4 of 5 (80)
Data quality, validity, and privacy assurance 8 0 1 8 of 8 (100)
Missing data 7 0 2 7 of 7 (100)
Analysis
Descriptive analysis, inferential analysis, and/or modeling 7 0 2 7 of 7 (100)
Confounders and modifiers 9 0 0 9 of 9 (100)
Heterogeneity of treatment effect 3 0 6 3 of 3 (100)
Sensitivity analysis 6 1 2 6 of 7 (85)
Discussions and conclusions
Bias 7 1 1 7 of 8 (87)
Ethics committee, IRB approval, or other ethical considerations 3 0 6 3 of 3 (100)
Interpretation 4 1 4 4 of 5 (80)
Dissemination 3 0 6 3 of 3 (100)
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ability of data elements or definitions.
Four (17%) of the elements were addressed by three or
fewer standards/guidelines (red in Table 1). This outcome
does not necessarily indicate disagreement between the
standards/guidelines. However, there is a lack of informa-
tion provided on the element by the majority, which is
evident by as many as six empty or silent standards/
guidelines. An example is communication with stake-
holders, which only two standards/guidelines addressed.
Eighteen of 23 elements (78%) included options or
choices for the researcher conducting the research. In terms
of all possible elements across all standards/guidelines,
19% (40 cells of the total 207 cells) offered choices. The
element of addressing confounders and modifiers was the
most frequently associated with choices (six standards/
guidelines). For example, rather than offering a single
approach for dealing with differences between the compar-
ator and intervention groups, a number of standards/
guidelines identified different methods or techniques (e.g.,
restriction, stratification, interaction, and so forth) to adjust
for these differences.
The level of detail and degree to which the standards/
guidelines are actionable differed. Within the 23 elements,
13 (57%) had actionable entries in all standards/guidelines
that addressed the element, such as study objectives and
research questions, sample size and statistical power, and
confounders and modifiers. Elements associated with the
research plan, such as the hypotheses, study protocol, studydesign, study limitations and potential confounders, popu-
lation, data sources, data linkage, sensitivity analysis, bias
and interpretation, had at least one standard/guideline entry
that was not actionable.3.2. Policy discussion
We used 23 criteria to compare nine prominent stan-
dards/guidelines for conducting observational studies and
found both similarities and important differences among
them. Over half (61%) of the 23 methodological elements
were included in at least seven of the standards/guidelines.
However, those standards/guidelines often disagreed based
on how those elements should be addressed or acted on.
Depending on which standard/guideline was followed,
research may miss important elements when viewed by
others or address an element differently than expected.
For some elements, these inconsistencies may have little
impact on variability in research quality or interpretation
(e.g., the use of PICOT to outline the research question). How-
ever, for other elements (e.g., how to handle missing data, the
need for a systematic review before conducting the research,
or adequacy of subgroup analysis to assess heterogeneity of
treatment effects), these inconsistencies may be problematic.
Inconsistencies across standards/guidelines may contribute to
methodological variation; disparities in what may be consid-
ered credible research by journal editors and peer reviewers;
and ultimately, what evidence is adopted by clinicians.
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observational research, a wide range of researchers have
the ability to conduct observational studies and increasing
numbers of studies will become available. A lack of
consensus regarding how observational studies should be
conducted may contribute to variability in interpretation
by clinicians, policy makers, and patients and whether that
research can or should influence decisions.
Different disciplines (e.g., epidemiology, pharmacovigi-
lance, and health economics) each have similar, but
different specific standards/guidelines. Bridging standards/
guidelines across the disciplines may increase awareness
across disciplines. To bridge these differences, we outline
considerations below on how and who should drive align-
ment and consensus for observational study methodologies.
In addition, we outline key considerations to ensure
ongoing support and adherence to established standards/
guidelines. This may serve to improve research conducted
as well as raise confidence in those trying to interpret study
results and to decide whether to use them.
3.2.1. Gaining alignment and consensus
Divergent views from different disciplines (e.g., bio-
statistics, econometrics, pharmacovigilance) and types of
stakeholders (e.g., patients, funders, researchers, and
decision makers) need to be considered in a consensus
process. Given the differences in audience and philosophy
(best practice vs. minimum standards), it is unlikely that
any one set of standards/guidelines will be acknowledged
by all stakeholders.
The nine standards/guidelines in our review were created
from six different organizational perspectives representing
public, private, and professional societies in theUnited States
and internationally. With a limited number of organizations
generating and updating standards/guidelines, creating a set
of commonly agreed on methods is feasible. However, with
the exception of PCORI, few organizations are likely to have
the authority, resources, or staff to convene public and private
thought leaders and a variety of stakeholders repeatedly.
Furthermore, there is diversity in focus for each organization
(e.g., PCOR-CER vs. pharmacovigilance). Therefore,
bringing all relevant organizations together in a voluntary
manner may be best to gain consensus. Audiences and
research focusesmay differ, but the elements of good practice
in conducting observational studies should not be different.
For example, with respect tomissing data, CER and epidemi-
ology may vary, but both would agree there is a need to
consider this element.
Consensus-based approaches have previously been used
to gain alignment across diverse stakeholders and perspec-
tives. These approaches have been used to develop quality
of care indicators, define appropriate use of ‘‘high cost/big
ticket’’ procedures, create clinical practice guidelines and
reporting guidelines such as PRISMA, and prioritize
research questions [1822]. Similar processes to gain
alignment on appropriate methods for the conduct,reporting, and evaluation of observational studies are
feasible and could bridge gaps among stakeholders.
A voluntary, consensus-based organization could foster
this effort. There is a long history of this approach in health
care, specifically in United States Pharmacopeia, such as
the National Council of Prescription Drug Programs,
Health Level 7, the National Quality Forum, and the
Council for Affordable Quality Healthcare Committee on
Operating Rules for Information Exchange, among others.
These organizations are typically open to all parties, allow
for debate across various stakeholders, include a broad
representation of different stakeholders, are facile and
iterative, and allow for open dialogue and discussion.
3.2.2. Identifying the level of consensus
Once a process is selected, it is important to determine
what level of consensus should be sought. Should
consensus standards/guidelines reflect best practices? Or
should they reflect a minimum bar? Observational studies
are used to inform different types of decisions, in which
more or less rigor may be required. Although some stake-
holders may advocate a set of aspirational best practices,
a consensus process is unlikely to identify a single set that
all stakeholders will agree on. For this reason, many of the
existing standards/guidelines (e.g., AHRQ, PCORI, and so
forth) have been outlined as a minimum set of standards/
guidelines. Some researchers have noted that a minimum
set of standards/guidelines may encourage rather than
discourage methods innovation.
We believe a set of minimum standards/guidelines rather
than best practices may be best. Beyond the minimum set,
groups could choose to add additional elements and steps
for their specific purposes. Over time, there is an opportu-
nity for consensus to develop on newer or more advanced
standards/guidelines gradually raising the bar. A set of
minimum standards/guidelines could be developed to
encourage uniformity, accessibility, and understandability
across both experts and nonexperts, thereby improving
the overall quality of research.
3.2.3. Accomplishing consensus
Gaining consensus could occur in a variety of forms. For
example, gathering all relevant stakeholders and organiza-
tions could be feasible at a single point in time. However,
as evidenced by the multiple iterations or editions of some
standards/guidelines (e.g., AHRQ registry handbook),
multiple and periodic meetings may be required to adapt
and incorporate new method development.
Quicker consensus across stakeholders may be feasible
for elements which are already considered important across
the nine standards/guidelines. More effort and time would
be required where there is disagreement on how to best
address the element or where the element has been addressed
by just a few organizations. Finally, there may be methods
which were not prioritized, but may rise to the level of prior-
itization when considered by various stakeholders. Among
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consensus, whereas others may require a more iterative
process and resources for an ongoing consensus-based
process.
3.2.4. Encouragement or enforcement
How to facilitate adoption of minimum standards/
guidelines is the next logical issue. Should it merely be
encouraged as guidance or should stronger measures be
applied to ensure adherence?
Some stakeholders could require or enforce adherence to
a set of methodological standards/guidelines. For example,
journal editors could support greater use of a common set
of standards/guidelines for research through publication
requirements. Funders could require adherence to the
minimum standards to obtain research funding. The Centers
for Medicare and Medicaid Services or other payers could
require research adherence to standards/guidelines as a
prerequisite to access claims data. Despite these individual
leverage points, to reach the greatest adoption, voluntary
approaches will also be needed. PCORI has designated
funding for dissemination and implementation. These funds
could assist in broader acceptance and use.
3.3. Limitations
Several limitations in our research approach may
account for some of the differences observed. First, all stan-
dards/guidelines were silent on certain topics. For example,
GRACE principles, GRACE 2.0 Checklist, and the
ENCePP Checklist do not mention review of prior research
to describe the study rationale or inform the study design.
The absence of information may represent a lack of agree-
ment that the specific elements are important or lower pri-
oritization by the author(s). Second, the information
provided by each standard/guideline may differ due to the
audience, research questions addressed, format, and philos-
ophy. Each standard/guideline was written for a specific
audience, such as researchers or decision makers who
may vary in their expertise. Included information was
tailored by scope, content, and arrangement for the specific
audience. Standards/guidelines focused on answering
PCOR research questions would have a distinct focus on
stakeholder engagement methods that would most likely
not be included in a pharmacovigilance standard/guideline.
Some standards/guidelines focused solely on conducting,
while others included reporting, and others considered both
activities. The content was presented in a variety of
formats, ranging from a multichapter manual to a list of
yes/no questions. The format and content influenced the
level of detail provided and style of writing. Our approach
was to excerpt the text verbatim and assume that the user of
the standard/guideline would use that single document to
assess the quality of a study. Finally, some standards/
guidelines sought to inform readers, others outlined best
practices, and others set minimum standards/guidelines.Variation in each of these elements could contribute to
the underlying differences across the standards/guidelines.
Some experts are concerned with standardizing methods
in a field which is rapidly evolving due to the availability of
new clinically rich data sources, analytic techniques, and
approaches to dealing with data. There are concerns that
standards/guidelines may impair methods innovation. We
found that a number of standards/guidelines allowed the
researcher, funder, or reader choice rather than a prescrip-
tive approach. This may allow data sources, analytic tech-
niques, and dissemination activities to continue to evolve.
The consideration of choice may note differential uses
(e.g., pharmacovigilance vs. PCOR-CER) or describe op-
tions for conducting research to inform different audiences.
4. Conclusion
From a policy perspective, many are seeking to under-
stand what standards/guidelines are important to base deci-
sions on and further who should be part of that process. The
quality of observational studies conducted should be
aligned regardless of the eye of the beholder or the stan-
dard/guideline by which an observational study is evalu-
ated. A common set of agreed on minimum standards/
guidelines could increase the likelihood of high-quality
research and adoption of observational studies results. If
successful, this effort would benefit funders of research as
they evaluate proposals, researchers as they apply agreed
on standards for conduct, and decision makers as they eval-
uate the quality of the research to inform their decisions.
Acknowledgments
The authors are grateful to the following experts for their
guidance and assistance: Douglas G. Altman, DSc, Univer-
sity of Oxford; David Atkins, MD, MPH, United States
Department of Veterans Affairs; Jesse A. Berlin, ScD,
Johnson & Johnson; Nancy Dreyer, MPH, PhD, Quintiles;
Mark Helfand, MD, MS, MPH, Oregon Health and Science
University; and Cynthia D. Mulrow, MD, MSc, University
of Texas Health Science Center. The experts do not neces-
sarily endorse this article, and the authors are solely respon-
sible for the contents and conclusions.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2015.10.014.
References
[1] Leung MY, Halpern MT, West ND. Pharmaceutical technology assess-
ment: perspectives from payers. J Manag Care Pharm 2012;18:256e64.
[2] Holtorf AP, Brixner D, Bellows B, Keskinaslan A, Dye J,
Oderda G. Current and future use of HEOR data in decision-
making in the US and emerging markets. Am Health Drug Bene-
fits 2012;5:428e38.
10 S.C. Morton et al. / Journal of Clinical Epidemiology 71 (2016) 3e10[3] Brixner DI, Holtorf A, Neumann PJ, Malone DC, Watkins JB. Stan-
dardizing quality assessment of observational studies for decision
making in health care. J Manag Care Pharm 2009;15:275e83.
[4] Sauerbrei W, Abrahamowicz M, Altman DG, Le Cessie S,
Carpenter J. STRengthening analytical thinking for observational
studies: the STRATOS initiative. Stat Med 2014;33:5413e32.
[5] PCORI (Patient-Centered Outcomes Research Institute) Methodol-
ogy Committee. The PCORI methodology report 2013. Available at
www.pcori.org/research-we-support/research-methodology-standards
Accessed September 10, 2015.
[6] Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group.
Preferred reporting items for systematic reviews and meta-analyses:
the PRISMA statement. Ann Intern Med 2009;151:264e9.
[7] Berger ML, Mamdani M, Atkins D, Johnson ML. Good research
practices for comparative effectiveness research: defining, reporting
and interpreting nonrandomized studies of treatment effects using
secondary data sources: the ISPOR good research practices for
retrospective database analysis task force reportdPart I. Value Health
2009;12:1044e52.
[8] Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML.
Good research practices for comparative effectiveness research:
approaches to mitigate bias and confounding in the design of non-
randomized studies of treatment effects using secondary data sources:
the International Society for Pharmacoeconomics and Outcomes
Research good research practices for retrospective database analysis
task force reportdPart II. Value Health 2009;12:1053e61.
[9] Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good
research practices for comparative effectiveness research: analytic
methods to improve causal inference from nonrandomized studies
of treatment effects using secondary data sources: the ISPOR good
research practices for retrospective database analysis task force
reportdPart III. Value Health 2009;12:1062e73.
[10] AHRQ Publication No. 12(13)-EHC099. In: Velentgas P, Dreyer NA,
Nourjah P, Smith SR, Torchia MM, editors. Developing a protocol
for observational comparative effectiveness research: a user’s guide.
Rockville, MD: Agency for Healthcare Research and Quality; 2013.
Available at. http://www.ncbi.nlm.nih.gov/books/NBK126190/ Ac-
cessed September 10, 2015.
[11] Berger ML, Martin BC, Husereau D, Worley K, Allen D, Yang W,
et al, On behalf of the, Ispor-Amcp- N. P. C. Retrospective Prospec-
tive Observational, CER Task Forces. A questionnaire to assess the
relevance and credibility of observational studies to inform health
care decision making: an ISPOR-AMCP-NPC good practice task
force report. Value Health 2014;17:143e56.[12] The European Network of Centres for Pharmacoepidemiology
and Pharmacovigilance (ENCePP). Checklist for study protocols
(revision 2). Available at: http://www.encepp.eu/standards_and_
guidances/checkListProtocols.shtml. Accessed September 10, 2015.
[13] The European Network of Centres for Pharmacoepidemiology and
Pharmacovigilance (ENCePP). Guide on methodological standards in
pharmacoepidemiology (revision 4). EMA/95098/2010. Available at:
http://www.encepp.eu/standards_and_guidances/methodologicalGu
ide.shtml. Accessed September 10, 2015.
[14] Department of Health and Human Services, Food and Drug Adminis-
tration, Center for Drug Evaluation and Research (CDER), Center for
Biologics Evaluation and Research (CBER). Guidance for industry:
good pharmacovigilance practices and pharmacoepidemiologic assess-
ment (pharmacovigilanceguidance) 2005.Available at http://www.fda.
gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf
Accessed September 10, 2015.
[15] Dreyer NA, Schneeweiss S, McNeil BJ, et al. GRACE principles:
recognizing high-quality observational studies of comparative effec-
tiveness. Am J Manag Care 2010;16:467e71.
[16] Dreyer NA, Velentgas P, Westrich K, Dubois R. The GRACE check-
list for rating the quality of observational studies of comparative
effectiveness: a tale of hope and caution. J Manag Care Spec Pharm
2014;20:301e8.
[17] PCORI (Patient-Centered Outcomes Research Institute) Methodology
Committee. The PCORI methodology report 2013. Available at http://
www.pcori.org/assets/2013/11/PCORI-Methodology-Report.pdf Ac-
cessed September 10 2015.
[18] Fink A, Kosecoff J, Chassin MR, Brook RH. Consensus methods:
characteristics and guidelines for use. Am J Public Health 1984;74:
979e83.
[19] Hall N, Hershey J, Kessler L, Stotts RC. A model for making project
funding decisions at the National Cancer Institute. Oper Res 1992;40:
1040e52.
[20] Linstone HA, Turoff M, editors. The Delphi method: techniques
and applications [Internet]. Newark (NJ): New Jersey: Institute of
Technology; 2002. Available at. http://is.njit.edu/pubs/delphibook/
Accessed September 10, 2015.
[21] Fleurence RL, Meltzer DO. Toward a science of research prioritiza-
tion? The use of value of information by multidisciplinary stake-
holder groups. Med Decis Making 2013;33:460e2.
[22] Fleurence RL, Selby JV, Odom-Walker K, Hunt G, Meltzer D,
Slutsky JR, et al. How the patient-centered outcomes research insti-
tute is engaging patients and others in shaping its research agenda.
Health Aff (Millwood) 2013;32:393e400.
